AAIPharma announces acquisition of Celsis Analytical Services

NewsGuard 100/100 Score

AAIPharma Services Corp. ("AAIPharma"), a leading provider of pharmaceutical product development services, announced today it has acquired Celsis Analytical Services, a division of Celsis International Ltd. that performs material testing services for the pharmaceutical, biotechnology and manufacturing sectors.

"The addition of Celsis Analytical Services will enable AAIPharma to expand its market presence in two key regions. Our combined company will bring a differentiated offering to the contract services market with an integrated development and material testing service model," said Patrick Walsh, CEO of AAIPharma. "We are excited to integrate Celsis labs' business with AAIPharma, creating one of the largest and most experienced materials testing businesses in the U.S."

Celsis Analytical Services provides cost-effective, outsourced cGMP-certified laboratory services with industry-leading sample turnaround times at its laboratory operations in Edison, N.J. and St. Louis. Both testing centers, comprising 65,000 square feet of laboratory facilities, will be additive to AAIPharma's existing 300,000 square feet of facilities. The combined entity offers a comprehensive menu of methods validation and testing services for biotechnology, pharmaceutical and consumer products manufacturers, raw materials suppliers and manufacturers of agricultural and veterinary medicine products.

"Celsis Analytical Services and AAIPharma have very complementary client bases and can provide a comprehensive range of testing services to the growing pharmaceutical and biotechnology outsourcing market," said Jay LeCoque, CEO of Celsis International Ltd. "This acquisition will enable each of the locations to participate more fully in the growth of the contract services market and to enjoy the synergies offered by the larger combined company."

"The material testing market is highly fragmented," added Walsh. "AAIPharma is responding to our diverse customer groups' growing preference to consolidate their outsourced services with fewer vendors. We recognize the opportunity to provide high quality, responsive and scalable services, and this acquisition is an example of our making substantial capital investments in equipment, facilities and capabilities."

Source:

AAIPharma Services Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Recycled food waste may be contaminated with pharmaceutical residues, research reveals